人乳头瘤病毒疫苗预防生殖器疣的有效性:基于2009-2017年卫生系统整合数据库的人群研究
该研究基于巴伦西亚卫生系统整合数据库(VID)2009-2017年真实世界数据,纳入14-65岁居民4,492,724人,其中14-23岁女性563,240人用于疫苗有效性估计。结果显示完整四价HPV疫苗接种对预防生殖器疣的有效性为74%(95% CrI 68-79),二价HPV疫苗在21岁以下女性中未见有效性,结果提示对未接种及接种二价疫苗女性可能存在间接保护。
要点
- 完整四价HPV疫苗方案预防生殖器疣的有效性为74%(95% CrI 68-79)。
- 21岁以下女性接种完整二价HPV疫苗方案未见有效性。
- 结果提示对未接种和接种二价疫苗女性可能存在间接保护。
核心结论
- 完整四价HPV疫苗接种方案在人群中减少生殖器疣的有效性为74%。
- 结果提示对未接种和接种二价HPV疫苗的女性存在间接保护。
研究设计与样本
- 基于巴伦西亚卫生系统整合数据库(VID)的人群回顾性队列研究,使用2009-2017年真实世界数据。
- 研究人群为2009-2017年居住在巴伦西亚地区的14-65岁所有居民,共4,492,724人。
- 疫苗有效性估计队列为563,240名14-23岁女性,随访观察。
- 生殖器疣 incident 病例定义为研究期间医院、初级和专科诊疗中首次激活生殖器疣相关编码(ICD-9-CM 078.11或ICD-10-CM A63.0)。
- 调整疫苗有效性通过负二项贝叶斯模型估计为(1-相对风险(RR))×100。
主要发现
- 总人群中共有23,049例生殖器疣病例,14-23岁女性队列中有2,565例。
- 总人群生殖器疣发病率为69.1/10万人年(95% CI 68.21-69.99),男性更高为72.73/10万人年(95% CI 71.45-74.04)。
- 年轻女性队列生殖器疣发病率为104.08/10万人年(95% CI 100.79-108.94)。
- 生殖器疣的相对风险从14岁至21岁随年龄增加,21至23岁达到平台期。
- 完整四价HPV疫苗方案的疫苗有效性为74%(95% CrI 68-79);21岁以下女孩完整二价HPV疫苗方案未见有效性。
关键数值与推荐
- 完整四价HPV疫苗方案预防生殖器疣的疫苗有效性为74%(95% CrI 68-79)。
- 21岁以下女孩完整二价HPV疫苗方案未见有效性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the effectiveness of the HPV vaccines in preventing genital warts (GW) in women aged 14-23 years and to estimate the incidence of GW in the whole population aged from 14 to 65. DESIGN: Population-based retrospective cohort study using real-world data from the Valencia health system Integrated Databases (VID). STUDY POPULATION: All subjects aged 14-65 years residing in the Valencia Region during 2009-2017 (n = 4,492,724), including a cohort of 563,240 females aged 14-23 years followed-up for the vaccine effectiveness (VE) estimations. MAIN OUTCOME MEASURES: Incident cases of GW defined as the first activation of GW-related codes (ICD-9-CM 078.11 or ICD-10-CM A63.0) in hospital, primary and specialized care during the study period. Adjusted VE was estimated as (1-Relative Risk (RR)) × 100 by a negative binomial Bayesian model. RESULTS: There were 23,049 cases of GW in the overall population and 2,565 in the females' cohort 14-23 years old. The incidence rate (IR) (in 100,000 persons-year) was 69.1 (95% CI 68.21-69.99) in the population overall, being higher in men (72.73; 95% CI 71.45-74.04). The IR of GW was 104.08 (95% CI 100.79-108.94) in the cohort of young women. The RR of GW increased with age from 14 to 21 years, reaching a plateau from 21 to 23. The VE of a complete schedule was 74% (95% CrI 68-79) for quadrivalent HPV vaccine (HPV4v). No effectiveness was seen with a full vaccination course with the bivalent HPV vaccine (HPV2v) in girls up to 21 years old. GW IR tends to be higher in unvaccinated cohorts covered by HPV4v vaccine than in unvaccinated cohorts not covered by HPV4v vaccine. CONCLUSIONS: A complete HPV4v vaccination schedule was 74% effective in reducing GW in our population. Our results also suggest an indirect protection to unvaccinated and HPV2v vaccinated girls.
引用
- Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, et al. Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009-2017. Vaccine. 2021. PMID: 34865874. doi:10.1016/j.vaccine.2021.11.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。